Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.89 |
| ▸ | GAA | P10253 | 5/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.89 |
| ▸ | TOP2A | P11388 | 5/20 | 0.89 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.89 |
| ▸ | LMNA | P02545 | 3/20 | 0.89 |
| ▸ | MEN1 | O00255 | 2/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.89 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.89 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.89 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.89 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.89 |
| ▸ | ATM | Q13315 | 1/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13818627 | 1.00 | CYP3A4 (0.89) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL15472841 | 1.00 | CYP3A4 (0.89) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL19959379 | 1.00 | CYP3A4 (0.89) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL10061877 | 1.00 | CYP3A4 (0.89) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL17816434 | 1.00 | CYP3A4 (0.89) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL94972 | 0.94 | CYP3A4 (0.81) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL15060571 | 0.94 | CYP3A4 (0.81) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL12308351 | 0.94 | CYP3A4 (0.81) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| SCHEMBL16606226 | 0.94 | CYP3A4 (0.81) | CYP3A4GAASMN1; SMN2TOP2ATOP2B | |
| Etoposide SCHEMBL24482748 | 0.94 | CYP3A4 (1.00) | CYP3A4GAASMN1; SMN2TOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180008719-A1 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-01-11 | — | — | US | disclosed |
| US-9610360-B2 | Polymer drug conjugates with tether groups for controlled drug delivery | CERULIEAN PHARMA INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160375145-A1 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY | ANGIOCHEM INC (CA) | 2016-12-29 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20150038429-A1 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY | ANGIOCHEM INC. (CA) | 2015-02-05 | — | — | US | disclosed |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-8828925-B2 | Etoposide and doxorubicin conjugates for drug delivery | ANGIOCHEM INC. (CA) | 2014-09-09 | — | — | US | disclosed |
| US-20130288986-A1 | POLYMER DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | INSERT THERAPEUTICS, INC | 2013-10-31 | — | — | US | disclosed |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8497365-B2 | Cyclodextrin-based polymers for therapeutics delivery | INSERT THERAPEUTICS, INC. | 2013-07-30 | — | — | US | disclosed |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120135914-A1 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY | ANGIOCHEM INC. (CA) | 2012-05-31 | — | — | US | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110282047-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375145-A1 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY | GLS, AQP4, ABCB1 | CYP3A4 297/4885GAA 1143/4885SMN1; SMN2 4463/4885 |
| US-20130288986-A1 | POLYMER DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | CD44, MSN, ABCB1 | CYP3A4 1063/4885GAA 533/4885SMN1; SMN2 1856/4885 |
| US-20120135914-A1 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY | GLS, AQP4, ABCB1 | CYP3A4 297/4885GAA 1143/4885SMN1; SMN2 4463/4885 |
| US-20180008719-A1 | POLYMERIC DRUG CONJUGATES WITH TETHER GROUPS FOR CONTROLLED DRUG DELIVERY | CD44, MSN, ABCB1 | CYP3A4 1419/4885GAA 581/4885SMN1; SMN2 1975/4885 |
| US-20130196906-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | CYP3A4 3210/4885GAA 66/4885SMN1; SMN2 422/4885 |
| US-20140255374-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | CYP3A4 4765/4885GAA 936/4885SMN1; SMN2 1548/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | CYP3A4 4765/4885GAA 936/4885SMN1; SMN2 1548/4885 |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | CYP3A4 4765/4885GAA 936/4885SMN1; SMN2 1548/4885 |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | CYP3A4 3210/4885GAA 66/4885SMN1; SMN2 422/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | CYP3A4 3210/4885GAA 66/4885SMN1; SMN2 422/4885 |
| US-20150038429-A1 | ETOPOSIDE AND DOXORUBICIN CONJUGATES FOR DRUG DELIVERY | GLS, AQP4, ABCB1 | CYP3A4 297/4885GAA 1143/4885SMN1; SMN2 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.